SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

Core Insights - SciSparc Ltd. has acquired an IP portfolio from Xylo Technologies, including the MUSE™ system, targeting the global multi-billion dollar GERD device market [1][4] - The MUSE™ system is designed for transoral fundoplication, a minimally invasive procedure for treating gastroesophageal reflux disease (GERD) [2] - SciSparc plans to commercialize these technologies immediately and aims for rapid market penetration and revenue generation [2] Market Opportunity - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, with a CAGR of 3.24% from 2025 to 2030 [5] - SciSparc intends to replicate Xylo's successful commercialization model from Greater China in high-growth regions like North America, Europe, and Latin America [3] Acquisition Details - SciSparc acquired the complete portfolio of patents and related intellectual property rights associated with the MUSE™ system, issuing shares that represent 19.99% of its outstanding share capital to Xylo [4]